ES2174852T3 - Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos. - Google Patents

Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.

Info

Publication number
ES2174852T3
ES2174852T3 ES93920354T ES93920354T ES2174852T3 ES 2174852 T3 ES2174852 T3 ES 2174852T3 ES 93920354 T ES93920354 T ES 93920354T ES 93920354 T ES93920354 T ES 93920354T ES 2174852 T3 ES2174852 T3 ES 2174852T3
Authority
ES
Spain
Prior art keywords
injuries
fabrics
systems
systemic treatment
catabolic states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920354T
Other languages
English (en)
Inventor
Andreas Sommer
Christopher A Maack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,936 external-priority patent/US5407913A/en
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2174852T3 publication Critical patent/ES2174852T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTA UN METODO PARA TRATAMIENTO DE PACIENTES CON ESTADOS CATABOLICOS, QUEMADURAS, TRAUMAS Y ULCERAS PEPTICAS Y PACIENTES QUE VAN A SER, ESTAN O ACABAN DE SER SOMETIDOS A INTERVENCION QUIRURGICA. EL METODO INCLUYE LA ADMINISTRACION DE UNA COMPOSICION QUE CONTIENE UN COMPLEJO DE FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA (IGF) Y PROTEINA-3 DE LIGAMIENTO DEL FACTOR DE CRECIMIENTO PARECIDO A INSULINA (IGFBP-3). LA FORMA PREFERIDA ES IGF-I/IGFBP-3.
ES93920354T 1992-08-26 1993-08-26 Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos. Expired - Lifetime ES2174852T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93589092A 1992-08-26 1992-08-26
US07/984,936 US5407913A (en) 1992-12-03 1992-12-03 Method and composition for systemic treatment of tissue injury

Publications (1)

Publication Number Publication Date
ES2174852T3 true ES2174852T3 (es) 2002-11-16

Family

ID=27130081

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920354T Expired - Lifetime ES2174852T3 (es) 1992-08-26 1993-08-26 Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.

Country Status (9)

Country Link
EP (1) EP0661990B1 (es)
JP (1) JPH08500827A (es)
AT (1) ATE215835T1 (es)
CA (1) CA2142455A1 (es)
DE (1) DE69331802T2 (es)
DK (1) DK0661990T3 (es)
ES (1) ES2174852T3 (es)
PT (1) PT661990E (es)
WO (1) WO1994004030A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093794A (en) * 1993-01-29 1994-08-15 Synergen, Inc. Wound healing composition
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
EP0800530A4 (en) * 1994-07-20 1998-12-02 Celtrix Pharma IGF / IGFBP COMPLEX FOR PROMOTING BONE TRAINING AND REGULATING BONE REMODELING
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
IL123383A0 (en) * 1995-09-14 1998-09-24 Bristol Myers Squibb Co Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6593290B1 (en) * 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
EP0981545B1 (en) * 1997-05-05 2006-09-13 Mayo Foundation For Medical Education And Research IGFIIE/ IGFBP2 complex
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
WO2020006273A1 (en) * 2018-06-27 2020-01-02 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN108998463A (zh) * 2018-08-24 2018-12-14 苏州红冠庄国药股份有限公司 一种人源胰岛素生长因子-1（igf-1）复合物的制备工艺

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
DK0661990T3 (da) 2002-06-17
EP0661990B1 (en) 2002-04-10
WO1994004030A1 (en) 1994-03-03
ATE215835T1 (de) 2002-04-15
DE69331802D1 (de) 2002-05-16
DE69331802T2 (de) 2002-11-07
EP0661990A1 (en) 1995-07-12
CA2142455A1 (en) 1994-03-03
EP0661990A4 (en) 1995-05-22
JPH08500827A (ja) 1996-01-30
PT661990E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
ES2174852T3 (es) Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
KR890700033A (ko) 외상치료 및 뼈 재생
SE8703625D0 (sv) New medical use
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
ATE187646T1 (de) Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
ES2067720T3 (es) Composicion y metodo para el tratamiento de la osteoporosis en mamiferos.
BR9206433A (pt) Formulação e processo para tratar ferimentos.
GR3021713T3 (en) The combination of growth hormone and insulin-like growth factor-i enhances growth
ZA89813B (en) Method for treating renal diseases
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
ES2140463T3 (es) Prevencion y tratamiento de la neuropatia periferica.
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
MX171116B (es) Composicion liquida para la curacion sin dolor de heridas
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
EP0726911A4 (en) TREATMENT OF IMMUNOLOGICAL AND HEMATOLOGICAL DISORDERS USING IGFBP ALONE OR ASSOCIATED WITH IGF
DE69310528T2 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
SE9303068D0 (sv) New use
SE9002731D0 (sv) Product comprising growth factor
SU1115731A1 (ru) Способ лечени послеожогового отека лица
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 661990

Country of ref document: ES